Association of SST5TMD4 and SST5TMD5 expression with metastasis and poor prognostic markers in gastroenteropancreatic neuroendocrine tumours

#4590

Introduction: The expression of the somatostatin receptor isoform SST5TMD4 is linked to poorer prognosis in somatotropinomas, as well as in breast and thyroid cancers, and it is notably overexpressed in gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Aim(s): This study aimed to explore the relationships between the various isoforms of the somatostatin receptor subtype 5, specifically SST5TMD4 and SST5TMD5, and the molecular pathways implicated in GEP-NET tumorigenesis.

Materials and methods: Tumour samples from 40 patients [20 pancreatic NETs (PanNETs) and 20 gastrointestinal NETs (GI-NETs)] were collected from 12 centres across Spain and analysed for mRNA transcript expression. Most samples were from Grade 2, non-secreting tumours, with a third of PanNETs and two-thirds of GI-NETs displaying metastasis.

Conference:

Presenting Author: Pedraza-Arevalo S

Authors: Pedraza-Arévalo S, Díaz-Pérez J, Garcia-Carbonero R, Villabona C, Capdevila J,

Keywords: GEP-NET, somatostatin, truncated receptor, metastasis,